The fecal calprotectin test rapidly determines inflammation levels in the gastrointestinal tract by detecting calprotectin levels in stool samples. Calprotectin is a neutrophil cytosolic protein abundantly released during inflammation in the intestines. The global fecal calprotectin test market is estimated to be valued at US$ 140.6 Mn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increased demand for noninvasive diagnostic tools for inflammatory bowel disease (IBD) diagnosis is driving the growth of the fecal calprotectin test market. Fecal calprotectin test provides a noninvasive option for detecting gastrointestinal inflammation and helps differentiate between irritable bowel syndrome and IBD without the need for invasive endoscopy. Its convenience and accuracy in measuring intestinal inflammation without uncomfortable procedures has resulted in rising adoption among IBD patients and healthcare providers for IBD screening and monitoring. This growing preference for noninvasive diagnostic techniques over traditional endoscopy is expected to propel the growth of the fecal calprotectin test market during the forecast period.
Segment Analysis
The global fecal calprotectin test market is dominated by test kits sub segment. Test kits account for over 70% of the overall market share owing to wide availability of these kits and their ease of use at point of care settings like physicians' offices and clinics. The prevalence of various GI disorders including inflammatory bowel disease is driving the demand for fecal calprotectin tests.
Key Takeaways
The global Fecal Calprotectin Test Market Share is expected to witness high growth over the forecast period of 2023 to 2030. The growth can be attributed to rising incidence of gastrointestinal disorders globally.
Regional analysis
North America is currently the dominant region in the fecal calprotectin test market. Growing awareness regarding diagnostic tests and presence of major players in the US is boosting market growth. However, Asia Pacific is expected to witness the highest growth rate owing to growth in healthcare expenditure and improving access to diagnosis in major markets like China and India.
Key players
Key players operating in the fecal calprotectin test market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc., ALPCO. Thermo Fisher Scientific Inc. and F. Hoffmann-La Roche Ltd. collectively account for over 40% share of the global market due to their robust product portfolio and global footprint.
Get more insights on this topic: https://www.newsstatix.com/fecal-calprotectin-test-market-outlook-analysis/
